Related Experiment Video
Updated: Apr 20, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Coronary artery bypass surgery or coronary stenting in diabetic patients: too soon to make a statement?
1Head Cardiac Unit, Otamendi Hospital, Buenos Aires School of Medicine.
Insights
Diabetic patients undergoing revascularization with first-generation drug-eluting stents (DES) face higher risks. New-generation DES show improved safety and reduced adverse events in this population.
Area of Science:
- Cardiology
- Interventional Cardiology
- Diabetology
Background:
- Diabetic patients historically exhibit poorer outcomes following percutaneous coronary interventions (PCI) and coronary artery bypass surgery (CABG).
- Early studies indicated increased major adverse cardiovascular events (MACE) with first-generation drug-eluting stents (DES) in diabetics compared to bare metal stents.
- Recent randomized trials (RCTs) have investigated newer DES generations in this high-risk group.
Purpose of the Study:
- To review existing and emerging randomized trial data on revascularization strategies in diabetic patients.
- To evaluate the safety and efficacy of different generations of DES in diabetic individuals.
- To identify unresolved questions regarding optimal revascularization in diabetes.
Main Methods:
- Review of recently published randomized clinical trials (RCTs) focusing on diabetic patients undergoing PCI or CABG.
- Analysis of data comparing first-generation DES, new-generation DES (biocompatible, biodegradable, absorbable), and bare metal stents.
- Assessment of major adverse cardiovascular events (MACE), including death, myocardial infarction, and stroke.
Main Results:
- First-generation DES were associated with a higher incidence of MACE in diabetic patients.
- Newer generation DES, including those with biocompatible, biodegradable, and absorbable polymers, demonstrated a better safety profile.
- Newer DES showed a reduction in adverse cardiac events compared to first-generation DES in diabetic populations.
Conclusions:
- Optimal revascularization strategy for diabetic patients remains an area with unresolved issues.
- Further RCTs utilizing next-generation DES, particularly complete absorbable scaffolds, are needed to definitively determine the best approach.
- The final efficacy of PCI versus CABG in diabetic patients requires further investigation with advanced stent technologies.
Abstract:
Diabetic patients have been associated with poor procedural and long term outcome if they were treated either with percutaneous coronary interventions or coronary artery bypass surgery. Recently several randomized clinical trials (RCT) in this subset of patients have been published showing a greater incidence of major adverse cardiovascular events, death/myocardial infarction/stroke, if they were treated with first generation drug eluting stents (DES) which was not observed previously in the bare metal stent era. However, almost simultaneously with this data, several RCT demonstrated better safety profile with new generation DES including biocompatible polymers, biodegradable polymers and lately complete absorbable DES, all of them showed reduction in adverse cardiac events compared to 1st generation DES in patients with diabetes. In this editorial we review the old and new randomized data in diabetic patients and conclude that there are many unresolved issues to make a definitive statement regarding which is the best revascularization preference in diabetic patients and the measured final efficacy of PCI and CABG will not be reached until the arrival of RCT using next generation DES, including complete absorbable scaffolds.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Cardiomyopathy V: Interprofessional Care
Acute Coronary Syndrome I: Introduction